23:59 , Aug 14, 2019 |  BC Extra  |  Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

Myriad falls on sales forecast, GeneSight concerns  Myriad Genetics Inc. (NASDAQ:MYGN) tumbled $19.05 (43%) to $25.50 Wednesday, the day after the molecular diagnostics maker reported 4Q revenues of $215 million, below FactSet’s consensus of $222...
19:30 , Aug 8, 2019 |  BC Innovations  |  Distillery Techniques

Nanoparticle-based system for nucleic acid therapy delivery and monitoring of disease progression in thoracic aortic dissection

TECHNIQUES CATEGORY: Drug delivery; imaging TECHNOLOGY: Nanoparticles; MRI A nanoparticle-based system could deliver a nucleic acid therapy to thoracic aortic dissections to treat and non-invasively monitor earlier progression of the disease, which current methods cannot...
00:51 , Aug 8, 2019 |  BC Extra  |  Financial News

Aug. 7 Financial Quick Takes: Allakos raises $350M; plus Exicure

Allakos raises $350M in upsized follow-on  Allakos Inc. (NASDAQ:ALLK) added $8.03 (10%) to $87.50 Wednesday after raising $350 million through the sale of 4.5 million shares at $77 in a bumped-up follow-on. The company had...
23:46 , Aug 5, 2019 |  BC Extra  |  Financial News

Aug. 5 Financial Quick Takes: Biotech tumbles with broader markets; plus Exo, 3-V and more

Biotech stocks take a hit  U.S. biotech stocks fell in line with the broader markets Monday, with the NASDAQ Composite, NYSE Arca Biotechnology Index (BTK), SPDR S&P Biotech ETF (XBI) and BioCentury 100 each losing...
03:18 , Aug 2, 2019 |  BC Innovations  |  Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
22:54 , Aug 1, 2019 |  BC Innovations  |  Product Development

NeuBase takes antisense oligos to more targets in more places

Newcomer NeuBase Therapeutics is re-engineering antisense oligos to access a broader range of targets, while simultaneously solving the modality’s dosing and delivery issues. With three approvals since the start of 2016, antisense oligonucleotides (ASOs) have...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
00:06 , Jun 25, 2019 |  BC Extra  |  Preclinical News

Alnylam preclinical data latest sign companies still plugging away at oral oligos

Proof-of-concept mouse data from Alnylam suggests the company has found a formulation that supports oral delivery of its oligonucleotide therapy, a long-standing goal in the field that has produced splashy deals but few clinical results....
00:38 , Jun 21, 2019 |  BC Innovations  |  Tools & Techniques

A human CRISPR-like system adds a new approach to regulating translation

A new system modeled on CRISPR and made entirely of human proteins is the latest strategy to intervene in gene control at the RNA translation level. The technology could bring higher levels of precision and...
22:46 , Jun 7, 2019 |  BC Innovations  |  Distillery Therapeutics

Oligoadenylate-conjugated benzimidazole-based miR-210 inhibitor for breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer In vitro and cell culture studies suggest a benzimidazole-based miR-210 inhibitor conjugated to a poly(A) oligonucleotide could help treat triple-negative breast cancer (TNBC). In vitro , a previously reported...